Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-04-12
2011-04-12
Bunner, Bridget E (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S387300, C530S809000, C530S350000, C424S133100, C424S070210
Reexamination Certificate
active
07923539
ABSTRACT:
Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
REFERENCES:
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6929932 (2005-08-01), Presnell et al.
patent: 2004/0016010 (2004-01-01), Kasaian et al.
patent: 2004/0136954 (2004-07-01), Grusby et al.
patent: 2005/0019343 (2005-01-01), Schenk
patent: 2006/0024268 (2006-02-01), Kasaian et al.
patent: 2006/0039902 (2006-02-01), Young et al.
patent: 2006/0159655 (2006-07-01), Collins et al.
patent: 2007/0128189 (2007-06-01), Sivakumar et al.
patent: 2005306757 (2004-04-01), None
patent: 03087320 (2003-04-01), None
patent: 2006057027 (2006-06-01), None
Stauber et al., “Crystal structure of the IL-2 signaling complex: Paradigm for a deterotrimeric cytokine receptor,”PNAS103(8):2788-1793, 2006.
Zhang et al., “Human IL-21 and IL-4 bind to partially overlapping epitopes of common γ-chain,”Biochem and Biophys Res Comm300:291-296, 2003.
Habib et al., “The common γ Chain (γc) Is a Required Signaling Component of the IL-21 Receptor and Supports IL-21-Indiced Cell Proliferation via JAK3,”Biochemistry41:8725-8731, 2002.
Olosz et al., “Structural Basis for Binding Multiple Ligands by the Common Cytokine Receptor γ-Chain,”J. Biol. Chem.277(14):12047-12052, 2002.
Brandt et al., “Generation of Antagonists by Amino Acid Replacement in the D-Helix of Human IL-21,”J. Leukocyte Biol.S2001, abstr. 119, 2001, Publisher Not Available.
Kasaian et al., “IL21 blocks IL15-induced NK cell expansion and enhances IFNγ production,”J. Leukocyte Biol.S2001, abstr. 76, 2001, Publisher Not Available.
Suto et al., “Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4-stimulated B cells,”Blood100(13):4565-4573, 2002.
Hecker et al., “Novel genetic variation of human interleukin-21 receptor is associated with elevated IgE levels, in females,”Genes and Immunity4:228-233, 2003.
Cohen et al., “Increased expression of CD132 and multiple IL-2 family receptors in psoriasis vulgaris,”J. Investigative Dermatol, abstr. 0115, 2003, Publisher Not Available.
Caruso et al., “A Functional Role for Interleukin-21 in Promoting the Synthesis of the T-Cell Chemoattractant, MIP-3α, by Gut Epithelial Cells,”Gastroenterology132:166-175, 2007.
Distler et al., “Inflammation-independent Overexpression of IL-21 Receptor mRNA in Keratinocytes from patients with Systemic Sclerosis,”American College of Rheumatology Abstract Supplement, abstr. 848, 2003, Publisher Not Available.
Brandt et al., “Interleukin-21 Inhibits Dendritic Cell-Mediated T Cell Activation and Induction of Contact Hypersensitivity In Vivo,”J. Invest. Dermatol.121(6):1379-82, 2003.
Brandt et al,, “Interleukin-21 inhibits dendritic cell activation and maturation,”Blood102(12):4090-4098, 2003.
Distler, “Overexpression of IL-21 Receptor mRNA in the Epidermis of Patients with Systemic Sclerosis: Lessions from the SCID Mouse Transplantation Model,”Annals of the Rheumatic Diseases63(S1):107, OP0158, 2004.
Alexopoulos et al., “Tolerance Induction Using IL-21 Antagonizing Fusion Protein,”Experimental Tolerance Induction I, Abstract #101, 2004.
O'Shea et al., “A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway,”Nature Reviews3:555-564, 2004.
O'Shea et al., “Jak3 and the pathogenesis of severe combined immunodeficiency,”Molecular Immunology41:727-737, 2004.
Wood et al., “IL-21 effects on human IgE production in response to IL-4 or IL-13,”Cellular Immunology231:133-145, 2004.
Jaspers Stephen R.
Sivakumar Pallavur V.
Bunner Bridget E
Hamud Fozia M
Lewis Michelle L.
Sawislak Deborah A.
ZymoGenetics Inc.
LandOfFree
IL-21 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-21 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-21 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720624